Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs

Carmela Coppola, Anna Rienzo, Giovanna Piscopo, Antonio Barbieri, Claudio Arra, Nicola Maurea

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

The side effects of anticancer drugs still play a critical role in survival and quality of life. Although the recent progresses of cancer therapies have significantly improved the prognosis of oncologic patients, side effects of antineoplastic treatments are still responsible for the increased mortality of cancer survivors. Cardiovascular toxicity is the most dangerous adverse effect induced by anticancer therapies. A survey conducted by the National Health and Nutrition Examination, showed that 1807 cancer survivors followed up for seven years: 51% died of cancer and 33% of heart disease (Vejpongsa and Yeh, 2014). Moreover, the risk of cardiotoxicity persists even with the targeted therapy, the newer type of cancer treatment, due to the presence of on-target and off-target effects related to this new class of drugs. The potential cardiovascular toxicity of anticancer agents includes: QT prolongation, arrhythmias, myocardial ischemia, stroke, hypertension (HTN), thromboembolism, left ventricular dysfunction and heart failure (HF). Compared to other cardiovascular disorders, the interest in QT prolongation and its complications is fairly recent. However, oncologists have to deal with it and to evaluate the risk-benefit ratio before starting the treatment or during the same. Electrolyte abnormalities, low levels of serum potassium and several drugs may favour the acquired QT prolongation. Treatment of marked QT prolongation includes cardiac monitoring, caution in the use or suspension of cancer drugs and correction of electrolyte abnormalities (hypokalaemia, hypomagnesaemia, hypocalcaemia). Syndrome of QT prolongation can be associated with potentially fatal cardiac arrhythmias and its treatment consists of intravenous administration of magnesium sulphate and the use of electrical cardioversion.

Original languageEnglish
Pages (from-to)135-143
Number of pages9
JournalCancer Treatment Reviews
Volume63
DOIs
Publication statusPublished - Feb 1 2018

Fingerprint

Drug Therapy
Pharmaceutical Preparations
Neoplasms
Therapeutics
Antineoplastic Agents
Electrolytes
Survivors
Cardiac Arrhythmias
Magnesium Sulfate
Electric Countershock
Hypokalemia
Hypocalcemia
Nutrition Surveys
Thromboembolism
Left Ventricular Dysfunction
Drug-Related Side Effects and Adverse Reactions
Intravenous Administration
Myocardial Ischemia
Heart Diseases
Suspensions

Keywords

  • Anticancer drugs
  • Cardiotoxicity
  • QT prolongation
  • Target therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Management of QT prolongation induced by anti-cancer drugs : Target therapy and old agents. Different algorithms for different drugs. / Coppola, Carmela; Rienzo, Anna; Piscopo, Giovanna; Barbieri, Antonio; Arra, Claudio; Maurea, Nicola.

In: Cancer Treatment Reviews, Vol. 63, 01.02.2018, p. 135-143.

Research output: Contribution to journalReview article

@article{e0e5829af76a4abc9bb3780d349d4935,
title = "Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs",
abstract = "The side effects of anticancer drugs still play a critical role in survival and quality of life. Although the recent progresses of cancer therapies have significantly improved the prognosis of oncologic patients, side effects of antineoplastic treatments are still responsible for the increased mortality of cancer survivors. Cardiovascular toxicity is the most dangerous adverse effect induced by anticancer therapies. A survey conducted by the National Health and Nutrition Examination, showed that 1807 cancer survivors followed up for seven years: 51{\%} died of cancer and 33{\%} of heart disease (Vejpongsa and Yeh, 2014). Moreover, the risk of cardiotoxicity persists even with the targeted therapy, the newer type of cancer treatment, due to the presence of on-target and off-target effects related to this new class of drugs. The potential cardiovascular toxicity of anticancer agents includes: QT prolongation, arrhythmias, myocardial ischemia, stroke, hypertension (HTN), thromboembolism, left ventricular dysfunction and heart failure (HF). Compared to other cardiovascular disorders, the interest in QT prolongation and its complications is fairly recent. However, oncologists have to deal with it and to evaluate the risk-benefit ratio before starting the treatment or during the same. Electrolyte abnormalities, low levels of serum potassium and several drugs may favour the acquired QT prolongation. Treatment of marked QT prolongation includes cardiac monitoring, caution in the use or suspension of cancer drugs and correction of electrolyte abnormalities (hypokalaemia, hypomagnesaemia, hypocalcaemia). Syndrome of QT prolongation can be associated with potentially fatal cardiac arrhythmias and its treatment consists of intravenous administration of magnesium sulphate and the use of electrical cardioversion.",
keywords = "Anticancer drugs, Cardiotoxicity, QT prolongation, Target therapy",
author = "Carmela Coppola and Anna Rienzo and Giovanna Piscopo and Antonio Barbieri and Claudio Arra and Nicola Maurea",
year = "2018",
month = "2",
day = "1",
doi = "10.1016/j.ctrv.2017.11.009",
language = "English",
volume = "63",
pages = "135--143",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Management of QT prolongation induced by anti-cancer drugs

T2 - Target therapy and old agents. Different algorithms for different drugs

AU - Coppola, Carmela

AU - Rienzo, Anna

AU - Piscopo, Giovanna

AU - Barbieri, Antonio

AU - Arra, Claudio

AU - Maurea, Nicola

PY - 2018/2/1

Y1 - 2018/2/1

N2 - The side effects of anticancer drugs still play a critical role in survival and quality of life. Although the recent progresses of cancer therapies have significantly improved the prognosis of oncologic patients, side effects of antineoplastic treatments are still responsible for the increased mortality of cancer survivors. Cardiovascular toxicity is the most dangerous adverse effect induced by anticancer therapies. A survey conducted by the National Health and Nutrition Examination, showed that 1807 cancer survivors followed up for seven years: 51% died of cancer and 33% of heart disease (Vejpongsa and Yeh, 2014). Moreover, the risk of cardiotoxicity persists even with the targeted therapy, the newer type of cancer treatment, due to the presence of on-target and off-target effects related to this new class of drugs. The potential cardiovascular toxicity of anticancer agents includes: QT prolongation, arrhythmias, myocardial ischemia, stroke, hypertension (HTN), thromboembolism, left ventricular dysfunction and heart failure (HF). Compared to other cardiovascular disorders, the interest in QT prolongation and its complications is fairly recent. However, oncologists have to deal with it and to evaluate the risk-benefit ratio before starting the treatment or during the same. Electrolyte abnormalities, low levels of serum potassium and several drugs may favour the acquired QT prolongation. Treatment of marked QT prolongation includes cardiac monitoring, caution in the use or suspension of cancer drugs and correction of electrolyte abnormalities (hypokalaemia, hypomagnesaemia, hypocalcaemia). Syndrome of QT prolongation can be associated with potentially fatal cardiac arrhythmias and its treatment consists of intravenous administration of magnesium sulphate and the use of electrical cardioversion.

AB - The side effects of anticancer drugs still play a critical role in survival and quality of life. Although the recent progresses of cancer therapies have significantly improved the prognosis of oncologic patients, side effects of antineoplastic treatments are still responsible for the increased mortality of cancer survivors. Cardiovascular toxicity is the most dangerous adverse effect induced by anticancer therapies. A survey conducted by the National Health and Nutrition Examination, showed that 1807 cancer survivors followed up for seven years: 51% died of cancer and 33% of heart disease (Vejpongsa and Yeh, 2014). Moreover, the risk of cardiotoxicity persists even with the targeted therapy, the newer type of cancer treatment, due to the presence of on-target and off-target effects related to this new class of drugs. The potential cardiovascular toxicity of anticancer agents includes: QT prolongation, arrhythmias, myocardial ischemia, stroke, hypertension (HTN), thromboembolism, left ventricular dysfunction and heart failure (HF). Compared to other cardiovascular disorders, the interest in QT prolongation and its complications is fairly recent. However, oncologists have to deal with it and to evaluate the risk-benefit ratio before starting the treatment or during the same. Electrolyte abnormalities, low levels of serum potassium and several drugs may favour the acquired QT prolongation. Treatment of marked QT prolongation includes cardiac monitoring, caution in the use or suspension of cancer drugs and correction of electrolyte abnormalities (hypokalaemia, hypomagnesaemia, hypocalcaemia). Syndrome of QT prolongation can be associated with potentially fatal cardiac arrhythmias and its treatment consists of intravenous administration of magnesium sulphate and the use of electrical cardioversion.

KW - Anticancer drugs

KW - Cardiotoxicity

KW - QT prolongation

KW - Target therapy

UR - http://www.scopus.com/inward/record.url?scp=85039872194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039872194&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2017.11.009

DO - 10.1016/j.ctrv.2017.11.009

M3 - Review article

AN - SCOPUS:85039872194

VL - 63

SP - 135

EP - 143

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

ER -